Nicholas W. Morrell
Cambridge, ENG CB20XY, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 224 publications
Interleukin-6 is critical in the development of pulmonary vascular disease in Gcn2-deficient mice.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 06, 2026
Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review.
Journal: Pulmonary circulation
Published: May 08, 2026
Tracking the evolution of biomarker efficacy in SARS-CoV-2: a global meta-analyses series.
Journal: Respiratory research
Published: November 13, 2025
BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
Journal: Angiogenesis
Published: April 01, 2025
Activin-A Regulates Bone Morphogenetic Protein Signaling in Pulmonary Endothelial Cells Without Affecting Bone Morphogenetic Protein Type-II Receptor Expression.
Journal: Pulmonary circulation
Published: March 12, 2025
Reply to the letter to the editor entitled "Bridging the species divide: The limits of rat models in capturing human PVOD mechanisms" by Perros F. et al.
Journal: Pulmonary circulation
Published: October 23, 2024
Navigating family dynamics and ethical considerations in genetic diagnosis of pulmonary arterial hypertension: insights from in-depth semi-structured interviews.
Journal: ERJ open research
Published: July 11, 2024
Functional validation of EIF2AK4 (GCN2) missense variants associated with pulmonary arterial hypertension.
Journal: Human molecular genetics
Published: April 09, 2024
Shared and Distinct Genomics of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Embolism.
Journal: American journal of respiratory and critical care medicine
Published: March 12, 2024
SEMA3G regulates BMP9 inhibition of VEGF-mediated migration and network formation in pulmonary endothelial cells.
Journal: Vascular pharmacology
Published: February 26, 2024
Last Updated: 09/26/2026